Xadago: latest news - GoINPHARMA
Monday, 22 April 2019 - 21:13


FDA approves Xadago (Zambon) for Parkinson’s treatment

Zambon Group announced today, jointly with Newron Pharmaceuticals and US WorldMeds, that FDA has approved Xadago (safinamide). Xadago is a treatment for Parkinson’s disease which acts as a selective MAO-B inhibitor, in combination with levodopa/carbidopa. The approval has been granted…

Xadago in Australia and New Zealand, Zambon, Seqirus to sign agreement

Zambon and Seqirus announced that they have entered into a long-term partnership covering Xadago (safinamide), Zambon’s product targeting Parkinson’s Disease, in Australia and New Zealand. Zambon will be responsible for product availability, while Seqirus will take charge of product registration…